The ILKAP Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 lung adenocarcinoma cell line, in which the ILKAP gene has been disrupted using CRISPR/Cas9 technology. This loss-of-function model enables investigation of the serine/threonine phosphatase ILKAP and its regulatory role in integrin-mediated signaling pathways.
The NCI-H1975 cell line (Homo sapiens) is a well-characterized model of non-small cell lung cancer (NSCLC), originally isolated from a female patient with lung adenocarcinoma. These epithelial cells harbor activating EGFR mutations L858R and T790M, which confer sensitivity to first- and second-generation EGFR tyrosine kinase inhibitors and are associated with acquired resistance mechanisms. The cell line??s tumorigenic properties and molecular profile make it particularly relevant for studying EGFR-mutant NSCLC biology, drug resistance, and metastasis.
ILKAP encodes a PP2C-type protein phosphatase that specifically dephosphorylates integrin-linked kinase (ILK) at key regulatory residues, thereby inhibiting ILK kinase activity. This negative regulation attenuates downstream phosphorylation of AKT1 and GSK3B, both critical nodes in pro-survival and migratory signaling. ILKAP functions within a macromolecular complex that includes ILK, PINCH1, and PARVA, which is recruited to integrin-rich adhesion sites following fibronectin engagement of ITGB1. By counteracting ILK-mediated signal transduction, ILKAP modulates the PI3K/AKT pathway and cross-talks with Wnt signaling, ultimately influencing cell adhesion, migration, and survival.
In the context of NCI-H1975 cells, disruption of ILKAP is expected to release the inhibitory constraint on ILK, leading to sustained or heightened activation of AKT and GSK3?? phosphorylation. This may amplify integrin-dependent oncogenic signals, contributing to enhanced cell adhesion dynamics, increased migratory and invasive capacity, and potentially altered responses to EGFR-targeted therapies. The model thus provides a valuable tool to dissect the contribution of phosphatase-mediated negative regulation to NSCLC progression and chemoresistance, particularly in the presence of EGFR-activating mutations.
Researchers can employ these polyclonal knockout cells to investigate the role of ILKAP in integrin signaling, cancer cell migration, and invasion using functional assays such as wound healing, transwell invasion, and cell adhesion on extracellular matrix substrates. The model is suitable for biochemical studies including Western blot analysis of phospho-AKT (Ser473) and phospho-GSK3?? (Ser9), ILK in vitro kinase assays, and co-immunoprecipitation to assess ILK-ILKAP complex integrity. Additionally, it facilitates drug response profiling under chemotherapeutic or EGFR inhibitor treatments to explore resistance mechanisms. For further technical details and availability, please contact Ascent Research.
